Multiple and Secondary Primary Cancers
Multiple and Secondary Primary Cancers is a research topic within Epidemiology. Science Explorer counts 24k research works in it since 1950. 9.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the epidemiology, clinical characteristics, and risk assessment of multiple primary cancers, also known as second primary neoplasms. It includes research on cancer survivorship, genetic susceptibility, cancer incidence, and population-based studies to understand the prevalence and impact of multiple primary cancers.
- Multiple Primary Cancers
- Second Primary Neoplasms
- Cancer Survivorship
- Risk of Second Primary Malignancies
- Clinical Characteristics
- Epidemiological Analysis
- Genetic Susceptibility
- Cancer Incidence
- Population-Based Study
- Cancer Registry Data
- Research works
- 24k fractional, since 1950
- In the world top 10%
- 2.4k per year above
- Top-10% rate
- 9.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +28% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Multiple and Secondary Primary Cancers research?
By volume, the United States and China publish the most (1.1k and 704 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.1k works
- 2 China 704 works
- 3 Japan 335 works
- 4 France 151 works
- 5 India 144 works
- 6 Italy 140 works
- 7 United Kingdom 137 works
- 8 Germany 134 works
- 9 South Korea 111 works
- 10 Russia 92 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Multiple and Secondary Primary Cancers research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Multiple and Secondary Primary Cancers research, followed by The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 32 works
- 2 The University of Texas MD Anderson Cancer CenterUnited States 27 works
- 3 Memorial Sloan Kettering Cancer CenterUnited States 21 works
- 4 Sun Yat-sen UniversityChina 15 works
- 5 Cleveland ClinicUnited States 15 works
- 6 Sichuan UniversityChina 15 works
- 7 Peking UniversityChina 14 works
- 8 Icahn School of Medicine at Mount SinaiUnited States 14 works
- 9 Dana-Farber Cancer InstituteUnited States 13 works
- 10 Moffitt Cancer CenterUnited States 11 works
Who are the leading researchers in Multiple and Secondary Primary Cancers?
The most-cited researchers publishing on Multiple and Secondary Primary Cancers include Elisabete Weiderpass, Ahmedin Jemal and Freddie Bray.
- 1 Elisabete Weiderpass France 6k citations
- 2 Ahmedin Jemal United States 4.9k citations
- 3 Freddie Bray France 4.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Multiple and Secondary Primary Cancers research done?
The largest centres of Multiple and Secondary Primary Cancers research in 2022–2025 are Beijing (China), Tokyo (Japan), New York (United States) and Shanghai (China).
Largest cities, 2022–2025
Where is the best place to study Multiple and Secondary Primary Cancers?
Among universities, judged by research, Chinese Academy of Medical Sciences & Peking Union Medical College, Fujian Medical University and Icahn School of Medicine at Mount Sinai score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 68.7 | 20.1% | 8.2× | 32 | +92.2% |
| 2 | Fujian Medical UniversityChina | 46.0 | 20.4% | 7.1× | 10 | +64.1% |
| 3 | Icahn School of Medicine at Mount SinaiUnited States | 44.0 | 9.2% | 7.0× | 14 | +100.5% |
| 4 | Karolinska InstitutetSweden | 37.3 | 12.6% | 4.6× | 8 | +55.1% |
| 5 | Harvard UniversityUnited States | 35.5 | 20.7% | 1.9× | 10 | +58.8% |
| 6 | Peking UniversityChina | 35.4 | 16.5% | 2.2× | 14 | +72.8% |
| 7 | Sichuan UniversityChina | 29.8 | 11.7% | 2.1× | 15 | +82.3% |
| 8 | Sun Yat-sen UniversityChina | 27.6 | 9.7% | 2.3× | 15 | +54.2% |
| 9 | Yale UniversityUnited States | 27.3 | 14.2% | 2.4× | 10 | +51.0% |
| 10 | Johns Hopkins UniversityUnited States | 23.3 | 16.2% | 1.9× | 8 | +5.5% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Multiple and Secondary Primary Cancers research growing?
Output in 2018–2022 was 28% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Multiple and Secondary Primary Cancers.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.